(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 July 2020 (16.07.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/146440 A1

(51) International Patent Classification:

A61K 31/496 (2006.01)	*A61K 31/4985* (2006.01)
A61K 45/06 (2006.01)	*A61K 31/506* (2006.01)
A61K 31/416 (2006.01)	*A61K 31/517* (2006.01)
A61K 31/4178 (2006.01)	*A61K 31/519* (2006.01)
A61K 31/4188 (2006.01)	*A61K 31/5377* (2006.01)
A61K 31/436 (2006.01)	*A61K 31/5517* (2006.01)
A61K 31/444 (2006.01)	*A61K 31/573* (2006.01)
A61K 31/4523 (2006.01)	*A61K 31/69* (2006.01)
A61K 31/4545 (2006.01)	*A61K 31/706* (2006.01)
A61K 31/4704 (2006.01)	*A61K 31/7076* (2006.01)
A61K 31/497 (2006.01)	*A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2020/012647

(22) International Filing Date:
08 January 2020 (08.01.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/790,326 09 January 2019 (09.01.2019) US

(71) Applicant: **CELGENE CORPORATION** [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US).

(72) Inventor: **WONG, Lilly, L.**; Celgene New Jersey Summit West, 556 Morris Avenue, Summit, NJ 07901 (US).

(74) Agent: **BHUMRALKAR, Megha** et al.; JONES DAY, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING MULTIPLE MYELOMA




FIG. 1

(57) **Abstract:** Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing multiple myeloma. The second active agent is one or more of a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an MEK inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BRD4 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an AURKB inhibitor, a BIRC5 inhibitor, a BET inhibitor, or a DNA methyltransferase inhibitor.

[Continued on next page]

WO 2020/146440 A1

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*